The purpose of this study is to evaluate the dose-dependent effects of glucosyl-hesperidin (CITRAPEAK) supplementation on exercise performance, recovery indicators, blood flow, cognitive function, mood, sleep, and fuel utilization in recreationally active adults.
Participants who are between 18 - 50 years of age
Body mass index values will range from >25.0 < 30.0 kg/m2
The average body mass index for entire study cohort will be less than 27.0 kg/m2. As such an ongoing calculation of the recruited cohort's mean body mass index will be maintained and people will only be randomized into the study if the average cohort body mass index value does not exceed 27.0 kg/m2
Free-living and independent
Not currently completing at least 180 minutes of moderate to vigorous exercise per week for the past 6 months
Positive medical history and/or is currently being treated for some form of heart disease, cardiovascular disease
Currently being treated for kidney disease, renal failure, or has dialysis performed on regular intervals
Has liver disease or some form of clinically diagnosed hepatic impairment
Lindenwood University
Lead sponsor
Increnovo LLC
Collaborator